Compare CRWD & PFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRWD | PFE |
|---|---|---|
| Founded | 2011 | 1849 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.5B | 145.4B |
| IPO Year | 2019 | N/A |
| Metric | CRWD | PFE |
|---|---|---|
| Price | $472.32 | $25.11 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 43 | 11 |
| Target Price | ★ $549.10 | $27.91 |
| AVG Volume (30 Days) | 2.5M | ★ 51.2M |
| Earning Date | 12-02-2025 | 02-03-2026 |
| Dividend Yield | N/A | ★ 6.74% |
| EPS Growth | N/A | ★ 131.89 |
| EPS | N/A | ★ 1.73 |
| Revenue | $4,565,168,000.00 | ★ $62,785,000,000.00 |
| Revenue This Year | $23.43 | N/A |
| Revenue Next Year | $21.95 | N/A |
| P/E Ratio | ★ N/A | $14.79 |
| Revenue Growth | ★ 22.05 | 3.89 |
| 52 Week Low | $298.00 | $20.92 |
| 52 Week High | $566.90 | $27.69 |
| Indicator | CRWD | PFE |
|---|---|---|
| Relative Strength Index (RSI) | 32.81 | 46.14 |
| Support Level | $504.54 | $24.92 |
| Resistance Level | $528.19 | $26.65 |
| Average True Range (ATR) | 16.90 | 0.59 |
| MACD | -4.03 | -0.04 |
| Stochastic Oscillator | 1.49 | 10.12 |
CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.